Ticagrelor in patients with acute coronary syndrome interventional treatment of Effect

SUN Xi-wen; ZHANG Can; LIN Qiu-wei

doi:10.3969/j.issn.1674-4055.2017.01.28

Abstract：Objective To explore the clinical effect of ticagrelor in patients with acute coronary syndromes undergoing interventional therapy.Methods 112 patients with acute coronary syndrome admitted in Gaozhou People's Hospital from February 2014 to May 2016 were randomly divided into the observation group and the control group, with 56 patients in each group. Patients in both groups were treated with percutaneous coronary stenting (PCI). On the basis of this, the patients in the observation group were treated with ticagrelor and the control group received clopidogrel. The changes of TIMI blood flow, platelet count and platelet aggregation rate were observed before and after treatment. The difference of adverse reactions between the two groups and the hemorrhage of the two groups were observed.Results There was no significant difference in TIMI blood flow between the two groups before treatment (P>0.05). The changes of TIMI blood flow in the two groups after treatment were significantly improved (P<0.05). Compared with the control group, the improvement was more obvious (P<0.05). There was no significant difference in platelet count between the two groups before treatment (P>0.05). After treatment, the platelet aggregation rate in the two groups decreased compared with that before treatment (P<0.05), and the decrease was more obvious in the observation group than that in the control group (P<0.05). The adverse reaction rate was 5.36%in the observation group and 17.86% in the control group. The adverse reaction rate in the observation group was significantly lower than that in the control group (P<0.05). The bleeding rate was 5.36% in the observation group and 7.14% in the control group. There was no significant difference in bleeding rate between the two groups (P>0.05). Conclusion Ticagrelor is clinically effective with fewer adverse reactions in interventional treatment of patients with acute coronary syndrome significant, which should be promoted.